Some adverse events occurred because of the treatment
59% of patients experienced a treatment delay or dose reduction, which are often used to help defend against unforeseen extra toxicity from the chemotherapeutic medications. Patients taking PIMs were more likely to have a treatment delay or dose reduction, though the association was insignificant.
There were also grade 3 or 4 treatment-related adverse events in 65% of the patients. Grade 3 refers to a severe toxic event as a result of chemotherapy. Grade 4 is a life threatening adverse event from the toxicity of the medication. This association between toxicity and PIMs, however, was significant.